Drugs & Targets FDA approves inavolisib + palbociclib + fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer October 11, 2024Vol.50 No.38
Drugs & Targets FDA clears the way for multi-center investigator-initiated study of Alpha DaRT in immunocompromised patients with recurrent cSCC October 11, 2024Vol.50 No.38
Drugs & Targets FDA grants clearance for radiation oncology tool to calculate absorbed dose of radionuclides October 11, 2024Vol.50 No.38
Drugs & Targets FDA approves neoadjuvant/adjuvant Opdivo for resectable NSCLC October 04, 2024Vol.50 No.37
Drugs & Targets FDA approves Retevmo for medullary thyroid cancer with RET mutation October 04, 2024Vol.50 No.37
Drugs & Targets FDA approves Cologuard Plus Test for non-invasive CRC screening October 04, 2024Vol.50 No.37
Drugs & Targets FDA approves Sarclisa + VRd for MM not eligible for transplant September 27, 2024Vol.50 No.36
Drugs & Targets Bayer submits sNDA to FDA for expanded indication for Nubeqa for treatment of mHSPC September 27, 2024Vol.50 No.36
Regulatory News Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover designThe agency accepts the invitation September 20, 2024Vol.50 No.35By Paul Goldberg
